Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Kswdeluxon Oct 17, 2021 3:11am
212 Views
Post# 34014549

RE:RE:ONCY Anticipated Milestones and Catalysts Q4 ' 2021

RE:RE:ONCY Anticipated Milestones and Catalysts Q4 ' 2021

Does anyone have the transcript from the May 19th, 2021 fire side chat.

I seem to recall that during that fire side chat or the one provious, ONC noted they anticipated having a partnership agreement in place before the end of 2021.
But I have seen no further discussion of that.
If ONC wants to start the Phase IIi triial with a funding partnership by end of H1 2022 they will have to announce something soon, as you don't just sign an agreement and start the trial the next day, it takes months to organize, so before end of H2 2021 still seems reasonable to me. At least hoping.
This is a potential milestone I have kept in the back of my mind. It is coming.

A missed mile stone is the final data of the AWARE-1 trial. I am hoping we see some real numbers in that as opposed to 'appears to be well tolerated'. I also recall that ONC cannot release that final data until Roche has approved it for release. ONC has been stating 'appears to be well tolerated' with some basic numbers already, if Roche has final approval on that, I suspect there will be more specific data to be released with real final numbers. Again hoping its not another flop NR.

Car-T agreements are another milestone that appears to be coming, but no idea when. i assume they are working on that. Hoping for sometihing in the next few months.

I am still expectinng Roche to step up to the plate after the release of the final data for AWARE-1 with either a buy out or a partnership agreement. Tecentriq is 66% of Roche's revenue and pela makes it work better. I see no advantange for Roche to wait for Pfiezer and Mereck to finalize the Bracelet and Irene, as Roche already know how pela effects Tecentriq.
The longer Roche sits back the more Pfiezer and Mereck will become interested and the greater the chance Roche could loose pela to Pfiezer or Mereck, and Roche needs pela to open the European markets to Tecentriq. So that is another milestone I am wating on to play out and see what happens there.
 

 I expect that if all my additional milestones are not met in 2021, they will happen before Q2 2022.

My opinion is, the next 6 months are going to be very exciting. More so than we have ever seen.

<< Previous
Bullboard Posts
Next >>